Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study
Open Access
- 29 November 2017
- journal article
- research article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 53 (7) , 834-844
Abstract
Background: Rabeprazole at 10 or 20 mg twice daily (b.i.d.) has been reported to be highly effective in the treatment of proton pump inhibitor (PPI)-resistant reflux esophagitis (RE) that is refractory to the standard once-daily PPI regimen. We evaluated the efficacy and safety of rabeprazole maintenance therapy at 10 mg once daily (q.d.) or b.i.d. for longer than 8 weeks.Methods: Patients with RE refractory to standard PPI regimens for at least 8 weeks were enrolled. They were treated with rabeprazole at 10 or 20 mg b.i.d. for 8 weeks during the open-label treatment period. After endoscopic examination, those with confirmed healing entered the subsequent double-blind maintenance therapy. During this period, the subjects were randomized to receive rabeprazole 10 mg q.d. (control) or 10 mg b.i.d. The primary endpoint was the endoscopic no-recurrence rate at Week 52.Results: In total, 517 subjects entered the treatment, and 359 subjects continued on maintenance therapy. The full analysis set for central assessment included 343 subjects. The no-recurrence rate at Week 52 was significantly higher in the b.i.d. group (73.9%;p < 0.001, χ2test) than in the q.d. group (44.8%). In particular, the b.i.d. regimen was more effective in all subgroups with Los Angeles Classification Grade B to D at treatment entry.Conclusions: In the maintenance treatment of PPI-resistant RE, rabeprazole at 10 mg b.i.d. exerted a stronger recurrence-preventing effect than 10 mg q.d. over 52 weeks. No particular safety issues were noted during long-term administration.ClinicalTrials.gov number: NCT02135107.Keywords
Funding Information
- Eisai Co., Ltd.
- EA Pharma Co., Ltd.
This publication has 34 references indexed in Scilit:
- Burden of Gastro-Oesophageal Reflux Disease in Patients with Persistent and Intense Symptoms Despite Proton Pump Inhibitor TherapyClinical Drug Investigation, 2011
- Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy: a prospective study in JapanJournal of Gastroenterology, 2010
- Nationwide epidemiological study on gastroesophageal reflux disease and sleep disorders in the Japanese populationJournal of Gastroenterology, 2008
- Maintenance Treatment for GERD: Residual Symptoms Are Associated with Psychological DistressDigestion, 2008
- Minimal changes in reflux esophagitis: red ones and white onesJournal of Gastroenterology, 2006
- Numerical modification of the Los Angeles classification of gastroesophageal reflux disease fails to decrease observer variationDigestive Endoscopy, 2003
- Acid suppression in gastro-oesophageal reflux disease: Why? How? How much and when?2002
- Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trialsClinical Therapeutics, 2001
- Basal acid output and gastric acid hypersecretion in gastroesophageal reflux diseaseDigestive Diseases and Sciences, 1994
- Comparison of omeprazole and ranitidine in treatment of refractory gastroesophageal reflux disease in patients with gastric acid hypersecretionDigestive Diseases and Sciences, 1992